Ventyx Biosciences: Strong Financial Position and Promising Pipeline Drive Buy Rating
Canaccord Genuity analyst Edward Nash has maintained their bullish stance on VTYX stock, giving a Buy rating on November 8. Edward ...
Ventyx Biosciences (VTYX) Gets a Buy from Oppenheimer
Oppenheimer analyst Jeff Jones maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target of ...
Ventyx Biosciences: Ready To Escape "The Crash Cycle"
Ventyx stock shows all the characteristics of a highly underappreciated issue with surprisingly valuable assets that can be ...
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Position Boosted by China Universal Asset Management Co. Ltd.
China Universal Asset Management Co. Ltd. lifted its stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report) by 64.1% ...
ETF Daily News26d
HC Wainwright Reiterates “Neutral” Rating for Ventyx Biosciences (NASDAQ:VTYX)
Ventyx Biosciences stock opened at $2.57 on Tuesday. The stock has a market cap of $181.62 million, a P/E ratio of -0.92 and a beta of 0.36. The company has a 50-day moving average price of $2.17 ...
KTLA27d
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that ...
Morningstar6d
Ventyx Biosciences Inc VTYX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Stockhouse27d
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral ...